Tuesday, December 11, 2012
Patrys Ltd., of Melbourne, Australia, said it completed initial treatment of the first group of three patients in its Phase I/IIa PAT-SM6 multiple myeloma trial. Each patient received four doses of the lead antibody candidate at a dose of 0.3 mg/kg, and no significant safety issues have been observed or reported to date.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.